2. AllCells is a leading provider of hematology-based
Products & Services to the world’s Life Science research
community
• >800 healthy & diseased human primary cell products that
enable advancement of scientific research
• Superior Supply-Chain and Efficient Work-Flow: Tissue
Collection Clinic, lab facilities, plus network of diseased tissue
providers
• Established 1998, headquartered in Emeryville, CA
• Global Reach: direct USA sales force + WW distribution via
STEMCELL Technologies (ROW) and VERITAS (Japan)
• Small and Minority Owned Business certification
About AllCells, LLCAbout AllCells, LLC
3. AllCells primary cell Products & Services are used in areas of
drug discovery & screening, stem cell research, regenerative
medicine, cell therapy, cell-based assays, cell biology research,
and other life science applications
Markets & ApplicationsMarkets & Applications
4. AllCells provides biologically relevant products that enable its
customers to advance early stage drug discovery & preclinical
development
Pharmaceutical Value ChainPharmaceutical Value Chain
6. LeukoLabLeukoLab
• Wholly owned IRB-certified human tissue collection clinic
(Emeryville, CA)
• largest volume bone marrow aspirates (up to 100 ml)
• whole blood collections
• r-GCSF mobilized and non-mobilized leukopheresis
• large repository human donors
• Staffed with RNs, Physicians, Phlebotomists
• Recruit human donors directly according to customer
criteria - active donor pool of >1,000 healthy volunteers
• Procedures comply with federal and California State Dept.
of Health Regulations
8. Hematopoietic Stem cells
AllCells provides Hematopoietic Stem Cells isolated from various
Human tissue:
• Bone Marrow
• Normal Peripheral Blood
• Mobilized Peripheral Blood
• Cord Blood
• Fetal Liver
• CD34+ and CD133+ cells from all tissue types
• Available fresh or frozen
• Certificate of Analysis and FACScan Analysis Report
Products: Stem/ProgenitorProducts: Stem/Progenitor
10. Bone Marrow
• Unprocessed Whole Bone Marrow
• Mononuclear Cells
• Stem/Progenitor Cells (CD34+ or CD133+)
• Marrow Stromal Cells (similar to
Mesenchymal Stem Cells)
• Endothelial Cells (CD105+)
• Erythroid Cells (CD71+)
• Myeloid Cells (CD33+)
• Granulocytes (Neutrophils, Basophils, and
Eosinophils)
ProductsProducts
11. ProductsProducts
Normal Peripheral Blood
• Leuko Pak (contains average 1.6X1010
MNCs)
• Processed Mononuclear Cells
• Stem/Progenitor Cells (CD34+ or CD133+)
• T Cells (Pan T, CD4+, and CD8+)
• B Cells (CD19+)
• Monocytes (CD14+)
• NK Cells (CD56+)
• Granulocytes (Neutrophils, Basophils, Eosinophils)
• Dendritic Cells (BDCA4+ Lymphoid Dendritic and
Monocyte derived Immature Dendritic)
• Plasma, platelets, pure RBCs
12. ProductsProducts
G-CSF Mobilized Peripheral Blood
• Leuko Paks 1-Day and 2-Day collections
• Processed Mononuclear Cells
• Stem/Progenitor Cells (CD34+ or CD133+)
• Early Erythroid Progenitor Cells (CD36+)
• T Cells (Pan T, CD4+, and CD8+)
• B Cells (CD19+)
• Monocytes (CD14+)
• NK Cells (CD56+)
• Dendritic Cells (BDCA4+ Lymphoid Dendritic and Monocyte
derived Immature Dendritic)
13. ProductsProducts
Cord Blood
• Processed Mononuclear Cells
• Stem/Progenitor Cells (CD34+ or CD133+)
• Early Erythroid Progenitor Cells (CD36+)
• T Cells (Pan T, CD4+, CD8+, Naive T Cells (CD4+/CD45RA+)
• B Cells (CD19+)
• Monocytes (CD14+)
• NK Cells (CD56+)
• Endothelial Cells (HUVEC)
• Granulocytes (Neutrophils, Basophils, Eosinophils)
• Plasma
14. Other ProductsOther Products
• Fetal Liver Cells
• Stem/Progenitor Cells (CD34+ or CD133+)
• Early Erythroid Progenitor Cells (CD36+)
• RNA/cDNA (available for all cells types provided from AllCells)
• Non-Human Primate Cells (Bone Marrow and Peripheral Blood)
• Processed Mononuclear Cells
• Granulocytes
• Plasma
• Bone Marrow Stem/Progenitor Cells (CD34+)
• Rat & Mouse Cells
• Rat Pancreatic islets and other hematopoietic cells from Rat and Mouse
• Canine Endothelial Cells (CVEC)
16. • ALL/AML
– Newly diagnosed
– Relapsed/Refractory
– Bone Marrow and Peripheral Blood
– Purified cells
• CLL/CML
– Newly diagnosed
– Relapsed/Refractory
– Bone Marrow and Peripheral Blood
– Chronic phase/accelerated or Blast Crisis
(CML)
• Multiple Myeloma
– Newly diagnosed
– Relapsed/Refractory
• Non-Hodgkin’s Lymphoma
– Burkitt’s Lymphoma (BL)
– Diffuse Large B Cell Lymphoma
(DLBCL)
– Follicular Lymphoma (FLL)
– Mantle Cell Lymphoma (MCL)
– Waldenstrom’s Macroglobulinemia
(WM)
• Polycythemia Vera (PV)
AllCells has established Supply Agreements with an
extensive network of oncology clinical sites
Comprehensive clinical reports are available for each
sample and specific lot at www.allcells.com prior to
purchase.
Oncology / Diseased ProductsOncology / Diseased Products
17. • Large Scale Processing & Cell Isolation:
• healthy or diseased human tissue
• molecular products (RNA/DNA, etc.) & lysates
• Drug Discovery Assay Services
• colony formation assays e.g. CFU-GM, CFU-Mk
• in vitro proliferation/inhibition assays (EC50)
• mechanistic studies
• toxicology
• Flow Cytometry Services
• immunophenotyping, rare cell analysis, sorting
• Custom assays
• cell cycle analysis
• apoptosis, phospho protein analysis, CD34+ determination under
ISHAGE guidelines
Custom ServicesCustom Services
18. Industry Leader: Since 1998 AllCells has provided hematology-based
products & services to the global Life Science industry
Market Applications: Drug discovery / toxicity, cell-based screening
assays, stem cell research, cell therapy, regenerative medicine, Dx /
biomarker discovery, gene expression
AllCells Competitive Advantage: Exceptional supply chain control -
donor recruitment (profiles of interest), G-CSF mobilization, healthy &
diseased tissue / cells, wholly owned IRB-certified clinic, fresh or frozen
products, guaranteed cell viability, clinical reports, hematology
expertise
Custom Services: Tissue sourcing, cell isolation, molecular products,
cell-based assays, drug screening/preclinical development
Sales: Direct Sales USA + International Distributors
Bus. Dev: Interested in collaborations / strategic partnerships
SummarySummary
19. Ernie Desmarais
Regional Account Manager
Northeast Region
edesmarais@allcells.com
Mobile: (617)997-2120
Office: (510)521-2600
Your Reliable
Source of Human
Primary Cells
Thank You !
Editor's Notes
We’re located about 20 min east of San Francisco just across the Bay Bridge
Jay is a Hematologist by training and has published…
- LeukoLab: Leukapheresis -mobilized (G-CSF) & non-mobilized, bone marrow aspirate, whole blood collection
Through the process of leukapheresis, blood is drawn from one arm with the help of a catheter that is placed in one of the veins. The blood is then removed from the arm and placed into a centrifuge. The centrifuge spins the blood and separates it into various components according to the materials’ weight and density. Consequently, the blood can be separated into red blood cells, white blood cells, and platelets. Typically, the white blood cells are removed and the rest of the cells and the blood plasma are returned to the body through another catheter or a needle in the opposite arm
- Gene expression includes protein expression & characterization
Target ID/Discovery Look for proteins or mRNA expressed (or not expressed) in a diseased state, identify new drugable targets, receptor binding, time-on-target, validate & optimize
Preclinical Development: Understand protein pathways & interactions, mechanism, ADME, safety, efficacy, dose ranging.
Lead Discovery: Evaluate lead compounds that can potentially fix the problem (primary & secondary screening)
Pre-Clinical: in-vitro & animal tests for toxicity & efficacy of therapy
Clinical Ph 1: small group (10’s) of healthy human volunteers to check safety & toxicity
Clinical Ph 2: Patient population (100’s) to determine efficacy, dosage & safety
Clinical Ph 3: larger patient population (1000’s) to determine efficacy, dosage, safety, side effects, and interactions
Competitive advantage
Competitive advantage
One area of focus is the
LeukoLab: Leukapheresis -mobilized (G-CSF) & non-mobilized, bone marrow aspirate, whole blood collection
Through the process of leukapheresis, blood is drawn from one arm with the help of a catheter that is placed in one of the veins. The blood is then removed from the arm and placed into a centrifuge. The centrifuge spins the blood and separates it into various components according to the materials’ weight and density. Consequently, the blood can be separated into red blood cells, white blood cells, and platelets. Typically, the white blood cells are removed and the rest of the cells and the blood plasma are returned to the body through another catheter or a needle in the opposite arm
LeukoLab: Leukapheresis -mobilized (G-CSF) & non-mobilized, bone marrow aspirate, whole blood collection
Through the process of leukapheresis, blood is drawn from one arm with the help of a catheter that is placed in one of the veins. The blood is then removed from the arm and placed into a centrifuge. The centrifuge spins the blood and separates it into various components according to the materials’ weight and density. Consequently, the blood can be separated into red blood cells, white blood cells, and platelets. Typically, the white blood cells are removed and the rest of the cells and the blood plasma are returned to the body through another catheter or a needle in the opposite arm
Naive T cells are able to respond to novel pathogens that the immune system has not yet encountered. Having adequate numbers of naive T cells is essential for the immune system to continuously respond to unfamiliar pathogens.
A naive T cell is considered mature, but is distinguished from activated T cells or memory T cells, as it is thought not to have yet encountered cognate antigen in the periphery. Naive T cells are able to respond to novel pathogens that the immune system has not yet encountered. Recognition by a naive T cell clone of its cognate antigen results in the initiation of an acquired immune response. In the ensuing response, the T cell acquires an activated phenotype (CD25+, CD44+, CD62Llow, CD69+), and may further differentiate into a memory T cell.
Naive T cells are able to respond to novel pathogens that the immune system has not yet encountered. Having adequate numbers of naive T cells is essential for the immune system to continuously respond to unfamiliar pathogens.
A naive T cell is considered mature, but is distinguished from activated T cells or memory T cells, as it is thought not to have yet encountered cognate antigen in the periphery. Naive T cells are able to respond to novel pathogens that the immune system has not yet encountered. Recognition by a naive T cell clone of its cognate antigen results in the initiation of an acquired immune response. In the ensuing response, the T cell acquires an activated phenotype (CD25+, CD44+, CD62Llow, CD69+), and may further differentiate into a memory T cell.
Competitive advantage
IRB approved program for collecting various oncology related samples from a variety of health institutions. Current access to over 2,500 patient samples through our developed sourcing network.
Three largest oncology groups in Bay Area collecting for AllCells’ program
Expanding collection sites on East Coast with new tissue samples expected May 2010
Ability to screen samples for higher blast counts depending on your research needs
Ability to provide samples based on donors’ demographic information (age, sex, weight, smoker, HLA type, etc.)
Multiple Myeloma:
We can provide either fresh whole tissue (30cc of Peripheral Blood or 25cc of Bone Marrow) or fresh isolated MNCs in concentrations of 10 million and 100 million cells. Easily able to supply 2-3 samples per week needed for your project
There are many subtypes of Non-Hodgkin lymphoma (NHL), including:
Burkitt lymphoma (or "Burkitt's tumor", or "Malignant lymphoma, Burkitt's type") is a cancer of the lymphatic system (in particular, B lymphocytes). It is named after Denis Parsons Burkitt, a surgeon who first described the disease in 1956 while working in equatorial Africa.[1][2]
Diffuse large B-cell lymphoma (DLBL, DLBCL, or DLCL) is a type of aggressive lymphoma. It accounts for approximately 40% of lymphomas among adults.[1] It is typically diagnosed between the ages of 25 and 40 years. It is twice as common in women as in men.
Follicular lymphoma is the most common of the indolent non-Hodgkin's lymphomas, and the second most common form of non-Hodgkin's lymphomas overall. It is defined as a lymphoma of follicle center B-cells (centrocytes and centroblasts), which has at least a partially follicular pattern. It is positive for CD10,[1] and usually negative for CD5
Mantle cell lymphoma (MCL) is one of the rarest of the non-Hodgkin's lymphomas (NHLs), comprising about 6% of NHL cases. MCL is a subtype of B-cell lymphoma, due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles. MCL cells generally over-express cyclin D1 due to a t(11:14)[2] chromosomal translocation in the DNA.
Polycythemia vera is a blood disorder in which the bone marrow makes too many red blood cells. Polycythemia vera may also result in the overproduction of white blood cells and platelets. Most of the health concerns associated with polycythemia vera are caused by a blood-thickening effect that results from an overproduction of red blood cells.
Waldenström's macroglobulinemia (WM, also known as lymphoplasmacytic lymphoma) is cancer involving a subtype of white blood cells called lymphocytes. The main attributing antibody is IgM. It is a type of lymphoproliferative disease, and shares clinical characteristics with the indolent non-Hodgkin lymphomas.
